{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T16:21:46Z","timestamp":1783441306868,"version":"3.54.6"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,4,15]]},"DOI":"10.7759\/cureus.58341","type":"journal-article","created":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T01:00:40Z","timestamp":1713229240000},"source":"Crossref","is-referenced-by-count":4,"title":["Sodium-Glucose Cotransporter 2 Inhibitor-Induced Euglycemic Diabetic Ketoacidosis: The Other Side of the Coin!"],"prefix":"10.7759","author":[{"given":"Sangita D","family":"Kamath","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umesh","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikki","family":"Shrivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.29652","article-title":"A literature review of the therapeutic perspectives of sodium-glucose cotransporter-2 (SGLT2) inhibitor-induced euglycemic diabetic ketoacidosis","volume":"14","author":"Patel K","year":"2022","unstructured":"Patel K, Nair A. A literature review of the therapeutic perspectives of sodium-glucose cotransporter-2 (SGLT2) inhibitor-induced euglycemic diabetic ketoacidosis. Cureus. 2022, 14:e29652. 10.7759\/cureus.29652","journal-title":"Cureus"},{"key":"ref2","unstructured":"European Medicines Agency. EMA confirms recommendations to minimise ketoacidosis risk with SGLT2 inhibitors for diabetes. (2016). Accessed. April 4, 2024: http:\/\/20162024."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.24911\/ejmcr\/173-1622061632","article-title":"A case report of sodium glucose co-transporter 2 inhibitor associated euglycemic diabetic ketoacidosis: a diagnostic challenge","volume":"6","author":"Richardson A","year":"2022","unstructured":"Richardson A, Vincent C. A case report of sodium glucose co-transporter 2 inhibitor associated euglycemic diabetic ketoacidosis: a diagnostic challenge. EJMCR. 2022, 6:11-16. 10.24911\/ejmcr\/173-1622061632","journal-title":"EJMCR"},{"key":"ref4","article-title":"High Anion Gap Metabolic Acidosis","author":"Brubaker RH","year":"2023","unstructured":"Brubaker RH, Vashisht R, Meseeha M. High Anion Gap Metabolic Acidosis. StatPearls Publishing, Treasure Island (FL); 2023."},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray JJ","year":"2019","unstructured":"McMurray JJ, Solomon SD, Inzucchi SE, et al.. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019, 381:1995-2008. 10.1056\/NEJMoa1911303","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer M","year":"2020","unstructured":"Packer M, Anker SD, Butler J, et al.. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020, 383:1413-24. 10.1056\/NEJMoa2022190","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.2337\/dci22-0034","article-title":"Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"45","author":"Davies MJ","year":"2022","unstructured":"Davies MJ, Aroda VR, Collins BS, et al.. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022, 45:2753-86. 10.2337\/dci22-0034","journal-title":"Diabetes Care"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2016.11.002","article-title":"SGLT2 inhibitor-associated diabetic ketoacidosis: clinical review and recommendations for prevention and diagnosis","volume":"38","author":"Goldenberg RM","year":"2016","unstructured":"Goldenberg RM, Berard LD, Cheng AY, Gilbert JD, Verma S, Woo VC, Yale JF. SGLT2 inhibitor-associated diabetic ketoacidosis: clinical review and recommendations for prevention and diagnosis. Clin Ther. 2016, 38:2654-64.e1. 10.1016\/j.clinthera.2016.11.002","journal-title":"Clin Ther"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-1721","article-title":"SGLT2 inhibitor-associated euglycemic diabetic ketoacidosis: a South Australian clinical case series and Australian spontaneous adverse event notifications","volume":"41","author":"Meyer EJ","year":"2018","unstructured":"Meyer EJ, Gabb G, Jesudason D. SGLT2 inhibitor-associated euglycemic diabetic ketoacidosis: a South Australian clinical case series and Australian spontaneous adverse event notifications. Diabetes Care. 2018, 41:e47-9. 10.2337\/dc17-1721","journal-title":"Diabetes Care"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.7861\/clinmed.2021-0045","article-title":"Association of British Clinical Diabetologists (ABCD) and Diabetes UK joint position statement and recommendations for non-diabetes specialists on the use of sodium glucose co-transporter 2 inhibitors in people with type 2 diabetes (January 2021)","volume":"21","author":"Dashora U","year":"2021","unstructured":"Dashora U, Gregory R, Winocour P, et al.. Association of British Clinical Diabetologists (ABCD) and Diabetes UK joint position statement and recommendations for non-diabetes specialists on the use of sodium glucose co-transporter 2 inhibitors in people with type 2 diabetes (January 2021). Clin Med (Lond). 2021, 21:204-10. 10.7861\/clinmed.2021-0045","journal-title":"Clin Med (Lond)"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.xkme.2019.12.006","article-title":"SGLT2 inhibitor-induced euglycemic diabetic ketoacidosis: a case report","volume":"2","author":"Wang KM","year":"2020","unstructured":"Wang KM, Isom RT. SGLT2 inhibitor-induced euglycemic diabetic ketoacidosis: a case report. Kidney Med. 2020, 2:218-21. 10.1016\/j.xkme.2019.12.006","journal-title":"Kidney Med"},{"key":"ref12","article-title":"Euglycemic Diabetic Ketoacidosis","author":"Plewa MC","year":"2023","unstructured":"Plewa MC, Bryant M, King-Thiele R. Euglycemic Diabetic Ketoacidosis. StatPearls Publishing, Treasure Island (FL); 2023."},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.12401","article-title":"Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: possible mechanism and contributing factors","volume":"7","author":"Ogawa W","year":"2016","unstructured":"Ogawa W, Sakaguchi K. Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: possible mechanism and contributing factors. J Diabetes Investig. 2016, 7:135-8. 10.1111\/jdi.12401","journal-title":"J Diabetes Investig"},{"key":"ref14","article-title":"Euglycemic diabetic ketoacidosis with SGLT2 inhibitor use in a patient on the Atkins diet: a unique presentation of a known side effect","volume":"4","author":"Sood M","year":"2018","unstructured":"Sood M, Simon B, Ryan KF, et al.. Euglycemic diabetic ketoacidosis with SGLT2 inhibitor use in a patient on the Atkins diet: a unique presentation of a known side effect. Clinical Case Rep. 2018, 4:104-7.","journal-title":"Clinical Case Rep"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.12330","article-title":"Case of ketoacidosis by a sodium-glucose cotransporter 2 inhibitor in a diabetic patient with a low-carbohydrate diet","volume":"6","author":"Hayami T","year":"2015","unstructured":"Hayami T, Kato Y, Kamiya H, et al.. Case of ketoacidosis by a sodium-glucose cotransporter 2 inhibitor in a diabetic patient with a low-carbohydrate diet. J Diabetes Investig. 2015, 6:587-90. 10.1111\/jdi.12330","journal-title":"J Diabetes Investig"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1186\/s12245-019-0240-0","article-title":"Euglycemic diabetic ketoacidosis associated with sodium-glucose cotransporter-2 inhibitor use: a case report and review of the literature","volume":"12","author":"Diaz-Ramos A","year":"2019","unstructured":"Diaz-Ramos A, Eilbert W, Marquez D. Euglycemic diabetic ketoacidosis associated with sodium-glucose cotransporter-2 inhibitor use: a case report and review of the literature. Int J Emerg Med. 2019, 12:27. 10.1186\/s12245-019-0240-0","journal-title":"Int J Emerg Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.45180","article-title":"A case of prolonged recovery for post-percutaneous coronary intervention (PCI) sodium-glucose cotransporter-2 (SGLT2) inhibitor-induced euglycemic diabetic ketoacidosis in a 28-year-old","volume":"15","author":"Petersen C","year":"2023","unstructured":"Petersen C, Gyabaah F, Sotelo J, Yohanna S, Deoker A. A case of prolonged recovery for post-percutaneous coronary intervention (PCI) sodium-glucose cotransporter-2 (SGLT2) inhibitor-induced euglycemic diabetic ketoacidosis in a 28-year-old. Cureus. 2023, 15:e45180. 10.7759\/cureus.45180","journal-title":"Cureus"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.4103\/jfmpc.jfmpc_644_21","article-title":"Euglycemic diabetic ketoacidosis associated with SGLT2 inhibitors: a systematic review and quantitative analysis","volume":"11","author":"Dutta S","year":"2022","unstructured":"Dutta S, Kumar T, Singh S, Ambwani S, Charan J, Varthya SB. Euglycemic diabetic ketoacidosis associated with SGLT2 inhibitors: a systematic review and quantitative analysis. J Family Med Prim Care. 2022, 11:927-40. 10.4103\/jfmpc.jfmpc_644_21","journal-title":"J Family Med Prim Care"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1177%2F2324709617710040","article-title":"Prolonged ketosis in a patient with euglycemic diabetic ketoacidosis secondary to dapagliflozin","volume":"5","author":"Pujara S","year":"2017","unstructured":"Pujara S, Ioachimescu A. Prolonged ketosis in a patient with euglycemic diabetic ketoacidosis secondary to dapagliflozin. J Investig Med High Impact Case Rep. 2017, 5:10.1177%2F2324709617710040","journal-title":"J Investig Med High Impact Case Rep"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.mehy.2018.02.025","article-title":"SGLT2 inhibitor-induced euglycaemic diabetic ketoacidosis may be due to abrupt, severe and transient impaired glucose sensing in susceptible individuals with a hitherto unrecognised beta cell SGLT variant","volume":"114","author":"Finucane FM","year":"2018","unstructured":"Finucane FM. SGLT2 inhibitor-induced euglycaemic diabetic ketoacidosis may be due to abrupt, severe and transient impaired glucose sensing in susceptible individuals with a hitherto unrecognised beta cell SGLT variant. Med Hypotheses. 2018, 114:11-12. 10.1016\/j.mehy.2018.02.025","journal-title":"Med Hypotheses"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.4158\/EP161292.PS","article-title":"American Association of Clinical Endocrinologists and American College of Endocrinology position statement on the association of SGLT-2 inhibitors and diabetic ketoacidosis","volume":"22","author":"Handelsman Y","year":"2016","unstructured":"Handelsman Y, Henry RR, Bloomgarden ZT, et al.. American Association of Clinical Endocrinologists and American College of Endocrinology position statement on the association of SGLT-2 inhibitors and diabetic ketoacidosis. Endocr Pract. 2016, 22:753-62. 10.4158\/EP161292.PS","journal-title":"Endocr Pract"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1089\/pancan.2018.0016","article-title":"Euglycemic diabetic ketoacidosis due to sodium-glucose cotransporter 2 inhibitor use in two patients undergoing pancreatectomy","volume":"4","author":"Pace DJ","year":"2018","unstructured":"Pace DJ, Dukleska K, Phillips S, Gleason V, Yeo CJ. Euglycemic diabetic ketoacidosis due to sodium-glucose cotransporter 2 inhibitor use in two patients undergoing pancreatectomy. J Pancreat Cancer. 2018, 4:95-9. 10.1089\/pancan.2018.0016","journal-title":"J Pancreat Cancer"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/246037-sodium-glucose-cotransporter-2-inhibitor-induced-euglycemic-diabetic-ketoacidosis-the-other-side-of-the-coin","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T01:00:43Z","timestamp":1713229243000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/246037-sodium-glucose-cotransporter-2-inhibitor-induced-euglycemic-diabetic-ketoacidosis-the-other-side-of-the-coin"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,15]]},"references-count":22,"URL":"https:\/\/doi.org\/10.7759\/cureus.58341","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4,15]]}}}